Jennifer L. Schehr

452 total citations
23 papers, 200 citations indexed

About

Jennifer L. Schehr is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jennifer L. Schehr has authored 23 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Jennifer L. Schehr's work include Cancer Immunotherapy and Biomarkers (8 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer Cells and Metastasis (6 papers). Jennifer L. Schehr is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer Cells and Metastasis (6 papers). Jennifer L. Schehr collaborates with scholars based in United States. Jennifer L. Schehr's co-authors include Joshua M. Lang, David J. Beebe, Scott M. Berry, Ticiana Leal, Jamie M. Sperger, David J. Guckenberger, Anwaar Saeed, David J. Niles, Jay W. Warrick and Erika Héninger and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jennifer L. Schehr

21 papers receiving 198 citations

Peers

Countries citing papers authored by Jennifer L. Schehr

Since Specialization

Citations

This map shows the geographic impact of Jennifer L. Schehr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer L. Schehr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer L. Schehr more than expected).

Fields of papers citing papers by Jennifer L. Schehr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer L. Schehr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer L. Schehr. The network helps show where Jennifer L. Schehr may publish in the future.

Co-authorship network of co-authors of Jennifer L. Schehr

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer L. Schehr. A scholar is included among the top collaborators of Jennifer L. Schehr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer L. Schehr. Jennifer L. Schehr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma 2025 ·Pigment Cell & Melanoma Research ·(unknown), (unknown), (unknown), Jennifer L. Schehr, Inmaculada Fernández, (unknown), Alexandre Marcelo Hintz, (unknown), (unknown), (unknown), Alexander Birbrair, Joshua M. Lang, T. Vincent	1
2	Sensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients. 2025 ·Journal of Clinical Oncology ·T. Vincent, Fauzia Osman, (unknown), (unknown), (unknown), Jennifer L. Schehr, Alexander Birbrair, Joshua M. Lang, Shuang Zhao	0
3	1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI) 2024 ·Annals of Oncology ·Joshua M. Lang, (unknown), Susan F. Slovin, Jamie M. Sperger, Jennifer L. Schehr, (unknown), Alexandre Marcelo Hintz, Hamid Emamekhoo, Dana E. Rathkopf, Wassim Abida, K. Autio, (unknown), A. Mitchell, (unknown), Shuang G. Zhao, Jens C. Eickhoff, Scott M. Dehm, (unknown), Christos E. Kyriakopoulos	1
4	Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer. 2024 ·Journal of Clinical Oncology ·T. Vincent, Yeonhee Park, (unknown), (unknown), (unknown), Jennifer L. Schehr, Alexander Birbrair, Shuang Zhao, Joshua M. Lang	1
5	Human CD4⁺iNKT cell adoptive immunotherapy induces anti‐tumour responses against CD1d‐negative EBV‐driven B lymphoma 2024 ·Immunology ·Dana C. Baiu, Akshat Sharma, Jennifer L. Schehr, Jayati Basu, (unknown), Makoto Ohashi, Eric Johannsen, Shannon C. Kenney, Jenny E. Gumperz	1
6	Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance. 2023 ·Journal of Clinical Oncology ·Amy K. Taylor, Jamie M. Sperger, Marina N. Sharifi, Yue Shi, (unknown), Jennifer L. Schehr, Hamid Emamekhoo, Christos E. Kyriakopoulos, Andrew J. Armstrong, Xiao X. Wei, Mary‐Ellen Taplin, Rana R. McKay, Shuang G. Zhao, Joshua M. Lang	1
7	Abstract B051: Alterations in SIRT2-H3K18Ac identify increased P300 activity in circulating tumor cells from patients with CRPC 2023 ·Cancer Research ·(unknown), Bing Yang, Jennifer L. Schehr, Anupama Singh, (unknown), John M. Denu, Joshua M. Lang, David F. Jarrard	0
8	Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial 2023 ·International Journal of Radiation OncologyBiologyPhysics ·M. Bassetti, (unknown), Nan Sethakorn, Joshua M. Lang, Jennifer L. Schehr, Shuang G. Zhao, Zachary S. Morris, Darya Buehler, Jens C. Eickhoff, Paul M. Harari, Anne M. Traynor, Toby C. Campbell, (unknown), Ticiana Leal	7
9	Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells 2023 ·Oncotarget ·(unknown), Bing Yang, Tanaya A. Purohit, Jennifer L. Schehr, Anupama Singh, (unknown), Peter W. Lewis, John M. Denu, Joshua M. Lang, David F. Jarrard	3
10	Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC). 2023 ·Journal of Clinical Oncology ·(unknown), Hamid Emamekhoo, (unknown), Petros Grivas, Moshe Chaim Ornstein, (unknown), (unknown), Jamie M. Sperger, (unknown), Jennifer L. Schehr, Amy K. Taylor, Yue Shi, Shuang G. Zhao, Joshua M. Lang	1
11	Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer 2022 ·Biomarker Research ·Jennifer L. Schehr, Nan Sethakorn, (unknown), (unknown), (unknown), (unknown), Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana Leal, Joshua M. Lang	4
12	Abstract 5121: Microfluidic characterization of circulating tumor cells from mouse models and patients with head and neck cancer 2022 ·Cancer Research ·(unknown), Caroline P. Kerr, Jennifer L. Schehr, (unknown), Zachary S. Morris, Joshua M. Lang	2
13	BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity 2021 ·Nucleic Acids Research ·(unknown), Peng Liu, Shengjie Zhang, (unknown), Yidan Wang, Jennifer L. Schehr, (unknown), (unknown), Li Lü, Lixin Rui, Xuehua Zhong, Kari B. Wisinski, Min Yu, Aussie Suzuki, Joshua M. Lang, Irene M. Ong, Wei Xu	43
14	Outcomes and safety analysis of a phase IB trial of stereotactic body radiotherapy (SBRT) to all sites of oligometastatic non-small cell lung cancer combined with durvalumab and tremelimumab. 2021 ·Journal of Clinical Oncology ·M. Bassetti, Nan Sethakorn, Joshua M. Lang, Jennifer L. Schehr, (unknown), Zachary S. Morris, Kristina A. Matkowskyj, Jens C. Eickhoff, (unknown), Anne M. Traynor, Narjust Duma, Toby C. Campbell, (unknown), Ticiana Leal	1
15	Clinical correlation of circulating tumor cell (CTC) PD-L1 and HLA I expression in metastatic renal cell carcinoma (mRCC) using exclusion-based sample preparation technology. 2020 ·Journal of Clinical Oncology ·Hamid Emamekhoo, Jennifer L. Schehr, (unknown), Xiao X. Wei, Rana R. McKay, Toni K. Choueiri, Joshua M. Lang	2
16	Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer 2020 ·Molecular Oncology ·Ashok Singh, Ryan A. Denu, (unknown), Jamie M. Sperger, Jennifer L. Schehr, (unknown), Karla Esbona, Richard J. Chappell, Beth A. Weaver, Mark E. Burkard, Joshua M. Lang	12
17	Integration of Magnetic Bead-Based Cell Selection into Complex Isolations 2018 ·ACS Omega ·(unknown), David J. Niles, Jennifer L. Schehr, David C. Beebe, Joshua M. Lang	21
18	Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction 2018 ·Lab on a Chip ·(unknown), David J. Guckenberger, Jennifer L. Schehr, (unknown), (unknown), Anupama Singh, (unknown), (unknown), (unknown), Jamie M. Sperger, Scott M. Berry, Joshua M. Lang, David J. Beebe	17
19	High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1 2016 ·PLoS ONE ·Jennifer L. Schehr, (unknown), Jay W. Warrick, David J. Guckenberger, (unknown), Jamie M. Sperger, Erika Héninger, Anwaar Saeed, Ticiana Leal, (unknown), Anne M. Traynor, Toby C. Campbell, Scott M. Berry, David J. Beebe, Joshua M. Lang	55
20	Abstract 3159: Identification of circulating tumor cells from renal cell carcinoma patients by a multi-parameter flow cytometry assay 2016 ·Cancer Research ·Joshua A. Desotelle, (unknown), Erika Héninger, Jennifer L. Schehr, Rana R. McKay, (unknown), Craig Norton, Toni K. Choueiri, Joshua M. Lang	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact